Mersana Therapeutics Adjusts Price Target to $36, Maintains 'Buy' Rating

Mersana Therapeutics (MRSN) received a reduced price target of $36.00 from Truist Securities, down 85.60% from the previous target of $250.00. Despite this, the "Buy" rating remains unchanged. Other analysts have also maintained a positive outlook, with an average target price of $99.83 and a consensus recommendation of 1.5, indicating "Buy" status. The estimated GF Value for MRSN in one year is $40.48, suggesting a potential upside of 435.45% from the current price.

Mersana Therapeutics (MRSN) has experienced a significant adjustment in its price target by Truist Securities, with the new target set at $36.00, a substantial decrease of 85.60% from the previous target of $250.00. Despite this reduction, Truist Securities maintains a 'Buy' rating on the stock, reflecting a positive outlook on MRSN's long-term prospects.

This adjustment follows a series of earnings reports and management discussions, with Truist Securities noting that their updated financial model drove the substantial reduction in the target valuation. The current price of MRSN is $7.26, down 78% over the past year.

Other analysts have also maintained a positive outlook on MRSN. The average one-year price target from six analysts is $99.83, with a high estimate of $325.00 and a low estimate of $8.00. This implies an average potential upside of 1,220.55% from the current price of $7.56. The consensus recommendation from eight brokerage firms is 1.5, indicating a "Buy" status. The GuruFocus estimated GF Value for MRSN in one year is $40.48, suggesting a potential upside of 435.45% from the current price.

The company's recent earnings report showed a 1.8% improvement in EPS to -$4.87 in Q2 2025, but the net loss widened to $24.3M. Total revenue rose 33.3% to $3.06M, driven by collaboration income. The stock price demonstrated significant volatility, surging 21.61% post-earnings and increasing 1,885.42% month-to-date.

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients with unmet needs. Its pipeline includes Dolasynthen, Immunosynthen, Emi-Le, XMT-2056, XMT-2068, and XMT-2175. The company anticipates reporting clinically meaningful data from its lead program, Emi-Le, in the latter half of 2025.

References:
[1] https://www.gurufocus.com/news/3062579/mrsn-truist-securities-adjusts-price-target-while-maintaining-buy-rating--mrsn-stock-news
[2] https://www.ainvest.com/news/mersana-therapeutics-2025-q2-earnings-slight-eps-improvement-widening-net-loss-2508/
[3] https://www.investing.com/news/analyst-ratings/truist-securities-slashes-mersana-stock-price-target-to-36-from-250-93CH-4193085